China Implements New Quality System To Strengthen Drug Safety; Puts Legal Onus On Drug Quality Attorneys
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA launched a new quality system April 10 that requires companies to assign responsibility for drug manufacturing to a drug quality administrator. The move builds accountability into drug manufacturers' systems
You may also be interested in...
What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 1 of 2)
SHANGHAI - Multinational pharma companies need to review their manufacturing practices to ensure full compliance with China's new GMP regulations, which went into effect March 1
What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 1 of 2)
SHANGHAI - Multinational pharma companies need to review their manufacturing practices to ensure full compliance with China's new GMP regulations, which went into effect March 1
China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March